Capodanno Davide, Ministeri Margherita, Cumbo Silvia, Dalessandro Veronica, Tamburino Corrado
Ferrarotto Hospital, University of Catania, Catania, Italy.
Catheter Cardiovasc Interv. 2014 May 1;83(6):907-12. doi: 10.1002/ccd.25153. Epub 2013 Aug 31.
Whether predicting the risk of early serum creatinine rise using the ratio of the volume of contrast media administered to the estimated creatinine clearance (V/CrCl) is applicable to the broader definition of contrast-induced nephropathy (CIN) (≥0.5 mg/dL absolute and/or 25% relative increase from baseline serum creatinine) is unknown.
A V/CrCl ≥4 has been proven to predict the risk of ≥0.5 mg/dL postprocedural absolute rise in serum creatinine.
A total of 722 patients undergoing coronary angiography ± percutaneous coronary intervention (PCI) between March 2011 and October 2011 with paired serum creatinine determinations at preprocedure and within 72-hr postprocedure were analyzed. The V/CrCl ratio was calculated by dividing the volume of contrast received by the patient's creatinine clearance. CIN using different definitions was termed as CINnarrow (rise in serum creatinine ≥0.5 mg/dL) and CINbroad (rise in serum creatinine ≥0.5 mg/dL and/or ≥25% increase in baseline serum creatinine).
The mean age was 66 ± 11 years and the mean baseline serum creatinine was 1.1 ± 0.8 mg/dL. Patients with V/CrCl ≥4 were significantly older and more frequently underwent ad hoc PCI compared with those with V/CrCl <4. CINnarrow and CINbroad were observed in 13 versus 3% (P < 0.001) and 23 versus 11% (P < 0.001) of patients with or without V/CrCl ≥4, respectively. After statistical adjustment, a V/CrCl ratio ≥4 remained significantly associated with the risk of both CINnarrow [adjusted OR 3.5, 95% confidence intervals (95% CI) 1.7-7.3; P < 0.001] and CINbroad (adjusted OR 2.5, 95% 1.6-3.9; P < 0.001).
A volume-to-creatinine clearance ratio ≥4 significantly predicts the risk of early postprocedural rise in serum creatinine regardless of the CIN definition adopted.
使用造影剂用量与估计肌酐清除率之比(V/CrCl)预测早期血清肌酐升高风险是否适用于更广泛定义的造影剂肾病(CIN)(血清肌酐绝对值升高≥0.5mg/dL和/或较基线血清肌酐升高25%)尚不清楚。
已证实V/CrCl≥4可预测术后血清肌酐绝对值升高≥0.5mg/dL的风险。
分析了2011年3月至2011年10月期间共722例行冠状动脉造影±经皮冠状动脉介入治疗(PCI)的患者,术前和术后72小时内均测定了配对的血清肌酐。V/CrCl比值通过将患者接受的造影剂体积除以肌酐清除率来计算。使用不同定义的CIN分别称为CIN窄(血清肌酐升高≥0.5mg/dL)和CIN宽(血清肌酐升高≥0.5mg/dL和/或基线血清肌酐升高≥25%)。
平均年龄为66±11岁,平均基线血清肌酐为1.1±0.8mg/dL。与V/CrCl<4的患者相比,V/CrCl≥4的患者年龄显著更大,且更频繁地接受急诊PCI。V/CrCl≥4和<4的患者中,CIN窄的发生率分别为13%和3%(P<0.001),CIN宽的发生率分别为23%和11%(P<0.001)。经过统计调整后,V/CrCl比值≥4仍然与CIN窄(调整后的OR 3.5,95%置信区间[95%CI]1.7-7.3;P<0.001)和CIN宽(调整后的OR 2.5,95%CI 1.6-3.9;P<0.001)的风险显著相关。
无论采用何种CIN定义,体积与肌酐清除率之比≥4均能显著预测术后早期血清肌酐升高的风险。